List Title | APhA DrugInfoLine

Endocrinology

SORT BY: Most Recent Most Viewed

July 17, 2017

Updated recommendations for glucocorticoid-induced osteoporosis

READ

PREVIEW
The American College of Rheumatology (ACR) released updated recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis in adults, children, and special populations....
June 20, 2017

Fracture risk increased with pioglitazone

READ

PREVIEW
Use of pioglitazone, an oral thiazolidinedione antihyperglycemic agent, was associated with an increased risk of bone fractures in insulin-resistant, nondiabetic patients with a recent history of...
June 12, 2017

Benefits and harms of osteoporosis medications in patients with CKD unclear

READ

PREVIEW
The safety and beneficial effects of osteoporosis medications on bone mineral density (BMD) and fracture risk in patients with chronic kidney disease (CKD) are unclear, according to results of a...
June 5, 2017

Levothyroxine not beneficial in subclinical hypothyroidism

READ

PREVIEW
Use of daily levothyroxine in older adults with subclinical hypothyroidism did not improve clinical outcomes compared with placebo, according to results of the TRUST trial published online in the...
May 16, 2017

New trial supports use of lixisenatide in older, nonfrail adults with type 2 diabetes

READ

PREVIEW
Use of once-daily lixisenatide (Adlyxin—Sanofi-Aventis) in older, nonfrail patients whose type 2 diabetes (T2D) was not controlled on their current antidiabetic regimen resulted in improvements in...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.